Table 1.
Demographic characteristics of participants with Alzheimer disease (n = 40), grouped based on their initial serum plasmalogen levels relative to those of healthy controls (n = 66)
| PlsEtn level | Sex | Age, yr | ApoE | PlsEtn level | Sex | Age, yr | ApoE |
|---|---|---|---|---|---|---|---|
| ≤ 25% | F | 89 | E3/4 | F | 89 | E4/4 | |
| M | 89 | E2/3 | F | 81 | E3/4 | ||
| M | 81 | E3/4 | F | 80 | E3/3 | ||
| M | 72 | E3/4 | 51%–75% | M | 78 | E4/4 | |
| F | 80 | E3/4 | F | 82 | E3/4 | ||
| 26%–50% | F | 82 | E3/4 | F | 86 | E3/4 | |
| F | 78 | E2/3 | M | 89 | E3/3 | ||
| F | 92 | E2/3 | M | 89 | E4/4 | ||
| F | 91 | E3/4 | M | 74 | E3/3 | ||
| F | 82 | E2/3 | M | 78 | E3/4 | ||
| F | 83 | E3/4 | M | 95 | E3/3 | ||
| F | 85 | E2/3 | F | 81 | E3/4 | ||
| F | 74 | E3/4 | M | 80 | E4/4 | ||
| M | 71 | E4/4 | F | 71 | E4/4 | ||
| F | 84 | E3/4 | M | 92 | E3/3 | ||
| M | 80 | E2/3 | > 75% | M | 81 | E4/4 | |
| F | 81 | E4/4 | M | 90 | E3/4 | ||
| F | 88 | E3/4 | F | 83 | E3/3 | ||
| F | 82 | E3/4 | F | 68 | E4/4 | ||
| M | 89 | E3/3 | F | 87 | E2/3 |
ApoE = apolipoprotein; F = female; M = male; PlsEtn = ethanolamine plasmalogen.